Research Interest Group:

Slides:

Advertisements

Similar presentations

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)

Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

Paula M. Jacobs, Ph.D. SAIC Frederick Cancer Imaging Program/DCTD/NCI/NIH September 5, 2006 Phase 0 Trials in Oncologic Drug Development DCTD Phase 0 Workshop.

@ PMCQ U October 19, Agenda l What is Advertising? l Pre-Launch Activities You Can Do l PAAB pre-NOC Meeting/Review policy.

Lasting Ethical Implication in Research: The Tuskegee Experience Sapana Panday Widener University.

National Coalition for Cancer Survivorship From Patient to Advocate: Your Role in Improving the United States Cancer Care System Kelsey Nepote, MSW Policy.

First International Psoriatic Arthritis Working Group Meeting: 8/15-17/03 NYC Philip Mease MD.

Sixth Annual Meeting March 12, :00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.

Abhijit S. Dighe, Ph. D Department of Orthopaedic Surgery University of Virginia SOM.

Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.

Research & Innovation International Rare Disease Consortium: Data Sharing Policy 3 rd International Traumatic Brain Injury Research Meeting Catherine BERENS.

The mission of the ONS Foundation is to support oncology nursing to improve the lives of people with or at risk for cancer.

Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.

Justina A. Molzon, MS Pharm, JD

European Society of Cardiology Cardiovascular diseases in women.

Systematic Reviews.

®® Practice based research networks (PBRN) have developed rapidly in the US in response to the pressing needs for research in routine clinical care. 1.

PROPOSAL FOR TIME-LINE AND ROAD-MAP OF STEM CELL R&D AND SERVICE AT RSCM/FKUI.

Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.

How science meets industry. Challenges for universities education education research researchcuriositydiscoverysurprise.

1 Safety of Cell Therapies Derived from Human Embryonic Stem Cells CTGTAC #45 April 10, 2008.

The International Society For Cellular Therapy. Mission Statement ISCT is a global association driving the translation of scientific research to deliver.

Industry Prospective Robin Bostic, Thoratec VP Health Policy and Health Economics INTERMACS Industry Sub-Committee Representative Our Future.

Team Building: Critical Role of Interdisciplinary Research Teams in Translational Research C. Kent Osborne, M.D. Director, Lester and Sue Smith Breast.

Role of the Drug Project Team in Formulating the Initial Development Plan of NCI-IND agents Jeff Moscow, MD IDB, CTEP.

FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on the Common Technical Document and Possibilities for New Topics.

Comments of International Society for Cellular Therapy (ISCT) to FDA Cellular, Tissue, & Gene Therapies Advisory Committee Elizabeth Read, MD March 30,

PhUSE Computational Science Working Groups Solutions Through Collaboration.

1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.

1 Intermacs 10 th Annual Meeting and Scientific Sessions Intermacs: Products for the Sites Friday, March 11, 2016: 7:00-8:30pm Omni Hotel, Grand Ballroom.

Watercooler Chat Moderated by: Ann Marie Queeney, Technical Editing SIG Manager July 10, 2015.

1 © 2007 Chapter 3 Strategic Planning for the EHR Migration Path.

Anne-Marie Yazbeck, PhD National Infoday, Sweden 2017

Public Policy analysis VAC CLASSES 2017

The Stages of a Clinical Trial

Michael E. Levin, Jacqueline Pistorello,

Patient Focused Drug Development An FDA Perspective

PATIENT FOCUSED DRUG DEVELOPMENT MEETING

GCP/QA SIAC Member Meeting 19 January 2007 Pamela Rose, Session Chair

Innovation for Healthier Americans

The National Sarcoma Survey 2015

EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.

Patient Empowerment in Oncology Birgit BEGER, ECCO CEO

Support- IRDiRC Proposed Work Plan And Communication Strategy

South Texas Psychiatric PBRN

Clinical Study Results Publication

Mapping Special Interest Group SNOMED IHTSDO

Hans Scheurer President Myeloma Patients Europe.

Helen Lee, European Commission

Changing the Game for Sjögren's Patients

Department of Medicine Michael Farkouh, Vice-Chair Research michael

FDA Advisory Committee for Lotronex

Progress Report on the Patient Reported Outcomes Harmonization Team

PhUSE Computational Science Working Groups

ICTMS Communicating Trial Results to participants

Troika Directors General Meeting Prague, 24 February 2009

Advance. Improve. Educate. Collaborate.

Theme: Translational Research - Conversation between Clinical and Basic Scientists Group 4 !

What is CICATS? The University of Connecticut, in partnership with regional hospitals, state agencies, and community health care organizations, has.

Data Visualizations Working Group

Cindy Murray NP Princess Margaret Cancer Centre

An FDA Statistician’s Perspective on Standardized Data Sets

Patient centred care & Concept of Multidisciplinary team (MDT) Mr A A Ayantunde, MD; FRCS; FWACS, FRCS (Gen & Colorectal Surgery) Consultant Laparoscopic.

Dr Manisha Shridhar Regional Advisor WHO-SEARO

Adults with Health Problems Who Have an Excellent Patient Experience Report Greater Support to Help Manage Their Health Condition Percent of adults 18–64.

Clinical Translation of Stem Cell Therapies: A Bridgeable Gap

Adults with Health Problems Who Have an Excellent Patient Experience Are Most Likely to Be Well-Informed About Their Prescription Medications Percent of.

Technology Title One-line Description Name, PhD Title Department

Natasa Rajicic, ScD July 31, 2019

Volume 26, Issue 7, Pages (July 2018)

Presentation transcript:

Research Interest Group: “Stem cells and osteogenesis” Quanjun (Trey) Cui, MD University of Virginia qc4q@virginia.edu Abhijit S. Dighe, Ph.D. University of Virginia asd2n@virginia.edu Stuart Goodman, MD, Ph.D. Stanford University goodbone@stanford.edu Lynne C. Jones, Ph.D. Johns Hopkins University ljones3@jhmi.edu Philippe Hernigou, MD Chu Henri Mondor philippe.hernigou@hmn.aphp.fr Organizers : Mission statement: The goal of this RIG is to bring scientists and clinicians, who are interested in stem cell therapy and osteogenesis, together to discuss reality versus hype of stem cells utility and future research directions. Agenda for Friday, March 9th, 2018; 6 PM to 8 PM, Hyatt Regency New Orleans, Celestin A-C (level 3) Session I : Presentations, 6:00 PM to 7:30 PM, moderator: Abhijit Dighe and Lynne Jones 5:45 PM to 6:00 PM: Assembly in the room, sign up, and food and drinks. 6:00 PM to 6:15 PM: Quanjun (Trey) Cui, “Stem cell therapy for bone repair: clinical perspective”. 6:15 PM to 6:30 PM: Stuart Goodman, “MSCs and Bone”. 6:30 PM to 6:45 PM: Abhijit S. Dighe, “Allogeneic mesenchymal stem cells (MSCs) for bone regeneration”. 6:45 PM to 7:00 PM: Philippe Hernigou, “Stem cell therapy in patients with history of cancer”. 7:00 PM to 7:15 PM: Stefan Zwingenberger, “European Regulatory Issues Related to Stem Cells Based Products for Bone Regeneration”. 7:15 PM to 7:30 PM: Lynne C. Jones, “Summary and Conclusions”. Session II: Open discussion, 7:30 PM to 8:00 PM. Moderators: Stuart Goodman, Lynne Jones and Quanjun (Trey) Cui. Goals for next 5 years: (1). To create an electronic platform to facilitate communication between the registered members, (2). To prepare a database of all the laboratories conducting research on utilization of MSCs for bone repair, (3). To prepare a comprehensive but easy to understand review of output of clinical trials carried out on MSCs therapy for bone regeneration to create awareness in general public for readiness of MSCs therapy, and (4). To create database of all the MSCs-based commercial products available in the market and to survey their efficiencies and efficacies. RIG seeks volunteers to formulate 4 committees to steer the efforts mentioned in the previous paragraph. Speakers for next year: US FDA, NIH, leading experts in MSCs, industries. Guidelines and future research directions : Purity of primary MSCs and use of cell lines, ISCT definition, selection of osteogenic MSCs, signaling pathways, pre-treatment, allogeneic MSCs and plan for sharing knowledge and resources. THANK YOU !